Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country.

"Everything we've seen happening over the last year or two in China goes in the right direction," Soriot said during the pharma's 1Q19 earnings call Friday.